Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224633 · ClinicalTrials.gov registry record · NA
A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin
A NA study of Acne Vulgaris, sponsored by Kenvue Brands.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT07224633: Completed NA study of Acne Vulgaris, sponsored by Kenvue Brands.
NCT07224633 is a NA study of Acne Vulgaris that has completed, run by Kenvue Brands. The registered enrollment target is 47 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224633, a NA study of Acne Vulgaris, has completed, sponsored by Kenvue Brands.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the tolerance and efficacy of a facial moisturizer in subjects with mild to moderate acne vulgaris over a 4-week treatment period.
Primary Outcome
The Investigator or the expert grader observed efficacy parameters like Visual Dryness, Tactile Surface Roughness, Lack of Radiance/Brightness, Global Fine Lines, Overall Appearance of Pores, Overall Skin Appearance, Skin Blotchiness, Uneven Skin Tone, Lack of Skin Clarity using a 10-point ordinal scale (0=none, 1-3 = mild, 4-6 = moderate, 7-9 = severe). A decrease in score compared to baseline indicates an improvement in the efficacy parameter.
Conditions Studied
Interventions
- OTHER Use of Barrier Building Moisturizer
Study Locations (1)
New Jersey
- TKL Research Inc. - Fair Lawn - Fair Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2025-12-16 |
| Phase | NA |
What the finished NCT07224633 record still lists
NCT07224633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Use of Barrier Building Moisturizer is the first listed.
NCT07224633 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT07224633 about?
NCT07224633 is a clinical study titled "A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin". The objective of this study is to evaluate the tolerance and efficacy of a facial moisturizer in subjects with mild to moderate acne vulgaris over a 4-week treatment period.
What is the current status of trial NCT07224633?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2025-10-07. Estimated completion is 2025-12-16.
What conditions does trial NCT07224633 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT07224633?
The interventions under investigation include: Use of Barrier Building Moisturizer (OTHER).
Who is sponsoring clinical trial NCT07224633?
This trial is sponsored by Kenvue Brands, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224633 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224633's enrollment target sits among peer trials
47 48th of 67 higher than 20 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Laser Treatment of Moderate to Severe Acne Vulgaris
ACTIVE NOT RECRUITING · NA
-
A Post Market Device Study for the Treatment of Acne
ACTIVE NOT RECRUITING · NA
-
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
COMPLETED · NA
-
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
COMPLETED · NA
-
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
COMPLETED · NA
-
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI